Innovent's SYCUME® Hits Primary Endpoint in Phase 3 Trial for…

Event summary

SYCUME® (Teprotumumab N01) met primary endpoint in Phase 3 RESTORE-3 trial for inactive thyroid eye disease (TED) in Chinese patients.
Proptosis response rate of 60.4% vs. 23.5% in placebo group, with a least squares mean change of -1.88 mm in study eye.
SYCUME® is the first IGF-1R antibody drug in China and the second approved worldwide, included in China's National Reimbursement Drug List since January 2026.
Trial enrolled 116 participants with inactive TED, demonstrating favorable safety profile with no new safety signals identified.

The big picture

Innovent's success in treating inactive TED with SYCUME® addresses a long-standing treatment gap, potentially shifting the standard of care from surgical interventions to pharmacological therapies. This milestone reinforces Innovent's leadership in the TED space and highlights the growing importance of targeted biologics in managing autoimmune diseases. The inclusion of SYCUME® in China's National Reimbursement Drug List also underscores the company's commitment to improving drug accessibility and affordability.

What we're watching

Market Expansion: Whether Innovent can leverage these results to expand SYCUME®'s market reach beyond China, particularly in regions with high TED prevalence.
Regulatory Dynamics: The pace at which additional regulatory approvals for SYCUME® could be secured in other major markets, given its inclusion in China's National Reimbursement Drug List.
Competitive Positioning: How SYCUME®'s efficacy and safety profile will compare against existing treatments like TEPEZZA®, and whether it can capture a significant share of the TED treatment market.